{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:21Z","timestamp":1791414141140,"version":"4.3.3"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Torezolid (TR-700) is the active moiety of the prodrug torezolid phosphate ([TP] TR-701), a second-generation oxazolidinone with 4- to 16-fold greater potency than linezolid against Gram-positive species including methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MRSA). A double-blind phase 2 study evaluated three levels (200, 300, or 400 mg) of oral, once-daily TP over 5 to 7 days for complicated skin and skin structure infections (cSSSI). Patients 18 to 75 years old with cSSSI caused by suspected or confirmed Gram-positive pathogens were randomized 1:1:1. Of 188 treated patients, 76.6% had abscesses, 17.6% had extensive cellulitis, and 5.9% had wound infections.\n            <jats:italic>S. aureus<\/jats:italic>\n            , the most common pathogen, was isolated in 90.3% of patients (139\/154) with a baseline pathogen; 80.6% were MRSA. Cure rates in clinically evaluable patients were 98.2% at 200 mg, 94.4% at 300 mg, and 94.4% at 400 mg. Cure rates were consistent across diagnoses, regardless of lesion size or the presence of systemic signs of infection. Clinical cure rates in patients with\n            <jats:italic>S. aureus<\/jats:italic>\n            isolated at baseline were 96.6% overall and 96.8% for MRSA. TP was safe and well tolerated at all dose levels. No patients discontinued treatment due to an adverse event. Three-stage hierarchical population pharmacokinetic modeling yielded a geometric mean clearance of 8.28 liters\/h (between-patient variability, 32.3%), a volume of the central compartment of 71.4 liters (24.0%), and a volume of the peripheral compartment of 27.9 liters (35.7%). Results of this study show a high degree of efficacy at all three dose levels without significant differences in the safety profile and support the continued evaluation of TP for the treatment of cSSSI in phase 3 trials.\n          <\/jats:p>","DOI":"10.1128\/aac.00076-10","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T09:45:25Z","timestamp":1291110325000},"page":"583-592","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":98,"title":["Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections"],"prefix":"10.1128","volume":"55","author":[{"given":"P.","family":"Prokocimer","sequence":"first","affiliation":[{"name":"Trius Therapeutics, Inc., 6310 Nancy Ridge Road, Suite 105, San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bien","sequence":"additional","affiliation":[{"name":"Trius Therapeutics, Inc., 6310 Nancy Ridge Road, Suite 105, San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Surber","sequence":"additional","affiliation":[{"name":"SERRG, Inc., 5210 Armour Road Suite 400, Columbus, Georgia 31904"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mehra","sequence":"additional","affiliation":[{"name":"eStudy Site, 752 Medical Center Court, Suite 105, Chula Vista, California 91911"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"DeAnda","sequence":"additional","affiliation":[{"name":"Trius Therapeutics, Inc., 6310 Nancy Ridge Road, Suite 105, San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Bulitta","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, 150 New Scotland Avenue, Albany, New York 12208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"Corey","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, 2400 Pratt Street, Durham, North Carolina 27705"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044194"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/606027"},{"key":"e_1_3_3_4_2","unstructured":"Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701 a novel oxazolidinone antibiotic. 2008"},{"key":"e_1_3_3_5_2","unstructured":"Safety of multiple ascending oral doses of TR-701 a novel oxazolidinone prodrug antibiotic. 2009"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/520655"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/533590"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01477-06"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00054-09"},{"key":"e_1_3_3_10_2","first-page":"89","volume":"2009","year":"2009","unstructured":"Butterfield, J., and T. P. Lodise, Jr. 2009. Vancomycin: is this the beginning of the end? Infect. Dis. Spec. Ed. 2009:89-95.","journal-title":"Infect. Dis. Spec. Ed."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/605560"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.2.269"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.01.012"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3051"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/596630"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-4-200802190-00204"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2138"},{"key":"e_1_3_3_18_2","first-page":"1544","volume":"39","year":"2004","unstructured":"Howden, B. P., P. D. Johnson, P. G. Charles, and M. L. Grayson. 2004. Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 39:1544.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/381202"},{"key":"e_1_3_3_20_2","first-page":"1925","volume":"15","year":"2009","unstructured":"Klein, E., D. L. Smith, and R. Laxminarayan. 2009. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg. Infect. Dis. 15:1925-1930.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.42.5.432"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08"},{"key":"e_1_3_3_24_2","unstructured":"Defining the impact of granulocytes on the kill of methicillin-resistant Staphylococcus aureus by the new oxazolidinone prodrug TR-701. 2009"},{"key":"e_1_3_3_25_2","unstructured":"Eur. Congr. Clin. Microbiol. Infect. Dis. 2009"},{"key":"e_1_3_3_26_2","first-page":"761","volume":"39","year":"2003","unstructured":"Mandell, L. A., and T. M. File. 2003. Short course treatment of community-acquired pneumonia. Clin. Infect. Dis. 39:761-763.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/428616"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.2.204"},{"key":"e_1_3_3_29_2","first-page":"1444","volume":"352","year":"2005","unstructured":"Miller, L. G., et al. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1444-1453.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"e_1_3_3_31_2","unstructured":"Effect of food on the pharmacokinetics of TR-701 a novel oxazolidinone antibiotic prodrug in healthy adult subjects. 2009"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.013755"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/592709"},{"key":"e_1_3_3_34_2","unstructured":"Hematological effects of TR-701 linezolid and placebo administered for 21 days in healthy subjects. 2008"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/648426"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00228-09"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00859-08"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm258"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/533593"},{"key":"e_1_3_3_40_2","unstructured":"Efficacy and safety of torezolid phosphate (TR-701) in a dose-ranging phase 2 randomized double-blind study in patients with severe complicated skin and skin structure infections (cSSSI). 2009"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1502.080010"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/588301"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2260-2266.2005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00076-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00076-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:24:38Z","timestamp":1645485878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00076-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1128\/AAC.00076-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00076-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"2010-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}